Paul G. Allen Frontiers Group [to 11 May 2019]
No new digest content identified.

BMGF – Gates Foundation [to 11 May 2019]
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 11 May 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 11 May 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 11 May 2019]
10 May 2019
ProMED Disease Outbreak Update
Ebola in the Democratic Republic of Congo, Chikungunya in Central and South America, Africa, Asia and the Indian Ocean.

Clinton Health Access Initiative, Inc. (CHAI) [to 11 May 2019]
No new digest content identified.

EDCTP [to 11 May 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 11 May 2019]
No new digest content identified.

European Medicines Agency [to 11 May 2019]
News and press releases
News: Working together for safe medicines in the EU

European Vaccine Initiative [to 11 May 2019]
No new digest content identified.

FDA [to 11 May 2019]
May 8, 2019
Statement from Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., and Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, on policies designed to capture more data to better understand effects of prescription drugs in pregnant and nursing women

Fondation Merieux [to 11 May 2019]
No new digest content identified.

Gavi [to 11 May 2019]
09 May 2019
Inactivated polio vaccine now introduced worldwide
[See Milestones above for detail]

GHIT Fund [to 11 May 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

Global Fund [to 11 May 2019]
Global Fund Partners with PharmAccess to Accelerate Universal Health Coverage in Africa
09 May 2019
The Global Fund today announced a partnership agreement with PharmAccess Foundation to support African countries accelerate progress toward universal health coverage by harnessing digital technology.

PMI and Global Fund Support Launch of Senegal-Gambia Cooperation in Fight Against Malaria
05 May 2019
Today, the governments of Senegal and The Gambia officially launched a joint campaign to distribute 11 million mosquito nets to fight malaria. This is the first cooperative effort to synchronize nationwide mass net distribution on both sides of an international border.

Hilleman Laboratories [to 11 May 2019]
No new digest content identified.

Human Vaccines Project [to 11 May 2019]
No new digest content identified.

IAVI [to 11 May 2019]
No new digest content identified.


No new digest content identified.

IFRC [to 11 May 2019]
Selected Press Releases, Announcements
World Red Cross Red Crescent Day: Celebrating “14 million points of hope”
Geneva, 8 May 2019 – On World Red Cross and Red Crescent Day 2019, the International Federation of Red Cross and Red Crescent Societies (IFRC) is celebrating the nearly 14 million Red Cross and Red Crescent volunteers around the world who provide a lif …

IVAC [to 11 May 2019]
No new digest content identified.

IVI [to 11 May 2019]
IVI News & Announcements
IVI hosts Environmental Impact Assessment Workshop
May 7, 2019

JEE Alliance [to 11 May 2019]
Selected News and Events
No new digest content identified.

MSF/Médecins Sans Frontières [to 11 May 2019]
Selected News; Project Updates, Reports [as presented on website]
Treating HIV in the cyclone-devastated city of Beira: “We cannot abandon them”
Project Update 9 May 2019

Measles epidemic declared in May 2018, still not under control one year on
Project Update 8 May 2019
Parts of Chad, including the capital, N’Djamena, and the city of Am Timan, are in the throes of a measles outbreak that has lasted for a year and is rising in intensity.
To help bring it under control, an emergency team from Médecins Sans Frontières (MSF) has carried out a mass vaccination campaign in Am Timan district, protecting 107,000 children against the potentially life-threatening disease…

Central African Republic
“We have not seen any doctors in Mingala for more than two years”
Project Update 7 May 2019

NIH [to 11 May 2019]
May 9, 2019
NIH awards will advance development of vaccines for sexually transmitted infections
— NIAID announces four new cooperative research centers.

NIH trial evaluates long-acting HIV medication unable to adhere to strict daily regimens
May 9, 2019 — LATITUDE study compares monthly injectable antiretroviral therapy to daily oral drugs.

PATH [to 11 May 2019]
No new digest content identified.

Sabin Vaccine Institute [to 11 May 2019]
No new digest content identified.

UNAIDS [to 11 May 2019]
Selected Press Releases/Reports/Statements
7 May 2019
UNAIDS and UN Women working together in Malawi

6 May 2019
Out-of-pocket expenses hamper access to HIV services
User fees and other out-of-pocket expenses―defined as direct payments made by people to health-care providers at the time of service use―are a major barrier to people getting tested for HIV, to people living with HIV being treated and to people living with HIV being retained in treatment and care.

UNICEF [to 11 May 2019]
Selected Statements, Press Releases, Reports
Press release
Nearly 900 children released from armed group in north-east Nigeria
New release brings total number of children released since 2017 to over 1,700

Vaccine Confidence Project [to 11 May 2019]
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 11 May 2019]
No new digest content identified.

Wellcome Trust [to 11 May 2019]
Q&A | 10 May 2019
“No matter where you live, our health and the world’s health depend on its most fragile link”
The 2019 Jimmy and Rosalynn Carter Humanitarian Award has been presented to our Director Jeremy Farrar in recognition of his work to improve global public health. Ahead of the award ceremony on 9 May, he spoke to the National Foundation for Infectious Diseases (NFID) about his career and the people who have influenced him.

The Wistar Institute [to 11 May 2019]
No new digest content identified.

World Organisation for Animal Health (OIE) [to 11 May 2019]
No new digest content identified.



BIO [to 11 May 2019]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 11 May 2019]
27 May 2019 to 30 May 2019
Advanced workshop: Vaccine Safety Monitoring and Pharmacovigilance
Sao Paulo – Brasil

IFPMA [to 11 May 2019]
No new digest content identified.

PhRMA [to 11 May 2019]
No new digest content identified.

Industry Watch [to 11 May 2019]
:: Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants
V114 Met Primary Endpoint by Demonstrating Noninferiority to PCV13 for all Shared Serotypes, and an Immune Response for Two Additional Serotypes
Data Support Continued Progression of Phase 3 Studies with V114
May 08, 2019 09:00 AM Eastern Daylight Time
KENILWORTH, N.J.– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from a Phase 2 trial (NCT02982972) evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, as compared to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age. In the study, designated V114-008, V114 met its primary endpoint by demonstrating noninferiority for the 13 serotypes contained in both vaccines. V114 also induced an immune response in infants for two additional disease-causing serotypes, 22F and 33F, which are not contained in PCV13. In January 2019, V114 received a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age. The FDA’s decision was informed in part by immunogenicity data from this Phase 2 study, V114-008, and the Phase 1/2 V114-005 study in healthy adults and infants. Results of the V114-008 study were presented during an oral session at the 37th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) in Ljubljana, Slovenia, and reinforce continued progression of Phase 3 clinical studies with V114.
“Children under the age of two are at increased risk for pneumococcal infection, which in some cases may lead to serious illnesses like pneumococcal pneumonia,” said Dr. David Greenberg, study investigator and physician in the Pediatric Infectious Disease Unit of Soroka University Medical Center in Beer-Sheva, Israel. “These Phase 2 data evaluating V114 in infants are encouraging and mark important progress to helping expand protection against pneumococcal disease for this vulnerable patient population.”…